Skip to main content
    P

    Pharming Group NV (PHAR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.63
    -0.01 (-0.10%)

    Market Cap: $668.14M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    34%(10/29)
    Avg Surprise
    -109.27%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.20
    Range$0.20 - $0.20
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.05+302.4%
    60d ago$0.07+177.8%
    30d ago$0.08+143.9%
    7d ago$0.08+143.9%
    Current$0.20
    Revenue Consensus
    $104M
    Range$98M - $108M
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.20
    Range$0.20 - $0.20
    1 analysts
    Revenue Consensus
    $88M
    Range$75M - $99M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.20---
    Sep 26EST
    		-$0.20---
    Jun 26
    Reported Jul 30
    		$0.02N/A-90.00%Miss+100.0%
    Mar 26
    Reported May 7
    		$-0.07$0.01-800.00%Miss-250.0%
    Dec 25
    Reported Mar 12
    		$0.07$0.01+498.29%Beat+1300.0%
    Sep 25
    Reported Nov 6
    		$0.01N/A+108.00%Beat+165.4%
    Jun 25
    Reported Jul 31
    		$0.01$-0.01+200.00%Beat+156.5%
    Mar 25
    Reported May 8
    		$-0.02$-0.02+0.00%Beat+0.0%
    Dec 24
    Reported Mar 13
    		$0.01$0.01-41.18%Miss+112.3%
    Sep 24
    Reported Oct 24
    		$-0.02$-0.00-512.00%Miss-253.0%
    Jun 24
    Reported Aug 1
    		$-0.02$-0.00-785.00%Miss-277.0%
    Mar 24
    Reported May 8
    		$-0.02$0.01-300.00%Miss+0.0%
    Dec 23
    Reported Mar 14
    		$-0.04$0.00-1002.22%Miss+80.2%
    Sep 23
    Reported Oct 26
    		$0.01$-0.01+200.00%Beat+0.0%
    Jun 23
    Reported Aug 3
    		$0.01$-0.02+150.00%Beat+0.0%
    Mar 23
    Reported May 11
    		$-0.02N/A+88.24%Beat-300.0%
    Dec 22
    Reported Mar 16
    		$-0.20$-0.21+2.38%Beat-1466.7%
    Sep 22
    Reported Oct 27
    		$0.01N/A-97.50%Miss+2100.0%
    Jun 22
    Reported Aug 4
    		$0.01$0.01+0.00%Beat-80.9%
    Mar 22
    Reported May 12
    		$0.01N/A-80.00%Miss-93.6%
    Dec 21
    Reported Mar 17
    		$0.01$0.02-25.00%Miss-86.9%
    Sep 21
    Reported Oct 28
    		$-0.00N/A-101.21%Miss-103.8%
    Jun 21
    Reported Aug 9
    		$0.05$0.10-47.60%Miss+347.9%
    Mar 21
    Reported Apr 7
    		$0.16$0.16-1.88%Miss+887.4%
    Dec 20
    Reported Mar 30
    		$0.11$0.11+4.00%Beat+845.5%
    Sep 20
    Reported Oct 29
    		$0.01N/A-89.00%Miss-35.0%
    Jun 20
    Reported Jul 30
    		$0.01N/A-92.20%Miss-32.4%
    Mar 20
    Reported Jun 29
    		$0.02N/A-86.75%Miss+39.5%
    Dec 19
    Reported Mar 30
    		$0.01N/A-93.95%Miss+8.0%
    Sep 19
    Reported Oct 24
    		$0.02N/A-88.72%Miss-22.2%
    Jun 19
    Reported Jul 26
    		$0.02N/A-85.58%Miss+106.0%
    Mar 19
    Reported Jun 29
    		$0.01$0.00N/ABeat+100.0%
    Dec 18
    Reported Mar 30
    		$0.01$0.00N/ABeat+13.1%
    Sep 18
    Reported Dec 31
    		$0.03$0.00N/ABeat+130.1%
    Jun 18
    Reported Sep 30
    		$0.01$0.00N/ABeat+149.1%
    Mar 18
    Reported Jun 29
    		$0.01$0.00N/ABeat+109.6%
    Dec 17
    Reported Mar 30
    		$0.01$0.00N/ABeat+177.3%
    Sep 17
    Reported Dec 31
    		$-0.09$0.00N/AMiss-
    Jun 17
    Reported Sep 30
    		$-0.02$0.00N/AMiss-
    Mar 17
    Reported Jun 29
    		$-0.06$0.00N/AMiss-
    Dec 16
    Reported Mar 30
    		$-0.01$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio321.00EV/EBITDA14.42x
    Price/FCF21.55xFCF Yield4.64%
    Profitability
    Profit Margin2.54%Operating Margin1.46%
    ROE3.65%ROIC5.39%
    Financial Health
    Debt/Equity0.36xInterest Coverage2.08x
    Current Ratio3.01xQuick Ratio2.31x
    Trading Statistics
    Beta0.07Avg Volume31.19K
    52-Week High$21.3452-Week Low$9.32

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$9.65
    SMA 20$10.06
    SMA 50$10.88
    SMA 200$14.15
    EMA 10$9.73
    EMA 20$10.02
    EMA 50$10.79
    EMA 200$12.81

    MACD

    Line: -0.41Signal: -0.42Hist: 0.01

    ADX

    ADX: 10.3+DI: 23.6-DI: 23.1

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down92.0
    PSAR$9.32

    Bollinger Bands

    Upper Band$11.10
    Lower Band$9.03
    %B Position2051%(Upper)
    Band Width0.29

    RSI (14-Day)

    Neutral
    37.9

    Momentum Oscillators

    Stoch %K15.5
    Stoch %D12.7
    Williams %R-77.5
    ROC (10d)-3.2%
    Momentum-0.32
    CCI (20d)-59.2
    MFI (14d)24.2

    Volatility Measures

    ATR (14d)$0.39(4.1%)
    StdDev (20d)0.52
    Hist Vol36.5%(Moderate)

    Volume Flow

    VWAP$9.72
    OBV221.7K
    AD Line-457.4K
    CMF (20d)-0.421

    Volume Metrics

    Avg Vol (20d)31.1K
    Vol Ratio0.2x(Low)
    VWMA (20d)$10.50

    Pivot Points

    R3$9.84
    R2$9.74
    R1$9.69
    Pivot Point$9.59
    S1$9.54
    S2$9.44
    S3$9.39

    Advanced Oscillators

    TSI-27.06
    Ultimate Osc36.4
    KST-129.02

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$90.21M$72.45M$106.50M$97.29M$93.22M$79.09M$92.70B$74.85M$74.09M$55.59M$81.87M$66.66M
    Cost of Revenue$14.54M$6.64M$21.10M$7.07M$8.97M$8.32M$12.20B$6.82M$7.98M$8.39M$7.16M$8.29M
    Gross Profit$75.67M$65.80M$85.40M$90.22M$84.25M$70.77M$80.50B$68.03M$66.11M$47.20M$74.71M$58.37M
    Operating Expenses$75.78M$71.09M$83.40M$74.47M$75.25M$78.20M$86.10B$64.70M$69.23M$63.51M$74.10M$56.46M
    R&D$32.26M$25.56M$32.10M$23.38M$23.70M$21.14M$22.30B$20.72M$21.60M$18.52M$11.70M$20.75M
    SG&A$14.95M$15.22M$20.00M$16.95M$20.50M$22.49M$51.60B$15.29M$15.62M$15.09M$30.48M$10.89M
    Operating Income$-111,000$-5,288,000$2.00M$15.75M$9.00M$-7,427,000$6.60B$3.33M$-3,121,000$-16,312,000$604,930$1.91M
    Interest Income$1.42M$3.24M$0$485,000$659,000$604,000$1.10M$825,000$920,000$1.78M$1.61M$1.25M
    Interest Expense$2.68M$2.69M$1.40M$7.95M$4,000$5.10M$0$3.00M$1.97M$1.56M$4.54M$1.65M
    Income Before Tax$3.04M$-4,753,000$4.80M$12.76M$7.08M$-11,788,000$6.70B$1.51M$-60,000$-16,624,000$-2,722,169$3.31M
    Income Tax Expense$1.40M$459,000$-500,000$5.21M$2.53M$3.10M$0$2.55M$1.16M$-4,176,000$705,747$-157,000
    Net Income$1.64M$-5,213,000$5.30M$7.55M$4.69M$-14,719,000$2.90B$-1,034,000$-1,218,000$-12,448,000$-2,722,169$3.46M
    EBITDA$8.75M$1.06M$9.41M$23.43M$9.79M$-4,108,000N/A$7.25M$1.91M$-9,147,000$8.17M$4.81M
    EBIT$5.71M$-2,058,000$6.20M$20.70M$7.08M$-6,690,000N/A$4.51M$2.87M$-15,068,000$604,930$1.91M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PHAR

    News

    Discipline and Rules-Based Execution in PHAR Response

    This article analyzes Pharming Group N.v. (NASDAQ: PHAR), indicating a near-term neutral sentiment that suggests a pause in mid and long-term weakness. It highlights a significant 72.0:1 risk-reward setup...

    Stock Traders Daily•10/15/26•Neutral

    A 13-person, 20-week leniolisib trial shows spleen shrinkage for Pharming (PHAR).

    Pharming Group N.V. presented positive topline results from a Phase II study of leniolisib in 13 participants with genetically identifiable primary immunodeficiencies (PIDs) and immune dysregulation. The study showed...

    Stock Titan•10/14/26•Bullish

    Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

    Pharming Group N.V. announced positive topline data from its Phase II trial of leniolisib for genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulation...

    Yahoo! Finance Canada•10/14/26•Bullish

    Spleen size fell in 10 of 11 trial participants taking an immune-disease drug

    Pharming (PHAR) announced positive Phase II topline data for leniolisib, showing significant improvements in genetically identifiable primary immunodeficiencies (PIDs) beyond APDS. The study revealed a 26.4% mean...

    Stock Titan•10/14/26•Bullish

    Pharming Group reports 26.4% spleen reduction in Phase 2 leniolisib trial

    Pharming Group reported a mean 26.4% reduction in spleen volume in a Phase 2 trial of leniolisib for genetic primary immunodeficiencies. The 13-person...

    Mugglehead Investment Magazine•10/14/26•Somewhat-Bullish

    PHAR Valuation and Fair Value

    P/E
    321.0x
    Forward P/E
    212.8x
    EV/EBITDA
    14.4x
    P/FCF
    21.6x
    P/B
    2.5x
    See GNG's fair value

    PHAR Profitability: Margins, ROIC and FCF

    Gross margin
    86.5%
    Operating margin
    1.5%
    Net margin
    2.5%
    ROIC
    5.4%
    ROE
    3.6%
    FCF margin
    8.6%
    FCF yield
    4.6%

    PHAR Competitors

    CompanyTicker
    4D Molecular Therapeutics IncFDMT
    OmniAb Inc.OABI
    Inventiva SaIVA
    Phreesia IncPHR
    Design Therapeutics IncDSGN
    Avalo Therapeutics IncAVTX
    MiMedx Group IncMDXG
    Performant Healthcare, IncPHLT

    Sector: Healthcare

    PHAR Analyst Ratings

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    0
    Buy
    4
    Hold
    0
    Sell
    0
    Strong Sell
    0

    PHAR Bull Case vs Bear Case

    Bear case

    • PHAR trades at 321.0x trailing earnings.
    • PHAR beat EPS estimates in 37.5% of its last 8 reported quarters.
    • PHAR's quarterly revenue changed -3.2% year over year.

    PHAR Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -79.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.20
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About PHAR

    Does PHAR pay dividends?

    Pharming Group NV (PHAR) does not currently pay a regular dividend.

    What is PHAR's P/E ratio?

    Pharming Group NV has a price-to-earnings (P/E) ratio of 321.00.

    What is PHAR's market cap?

    Pharming Group NV (PHAR) has a market capitalization of $668.14M with a current stock price of $9.63.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In